Recombinant Human NKp44/NCR2 Fc Chimera Avi-tag Protein, CF

When Recombinant Human PDGF-DD (1159-SB/CF) is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human NKp44/NCR2 Fc Chimera Avi-tag (Catalog # AVI2249) binds with an ED50 of 0.200-1.60 µg/mL.

2 μg/lane of Recombinant Human NKp44/NCR2 Fc Chimera Avi-tag Protein (Catalog # AVI2249) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 60-70 kDa and 120-150 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human NKp44/NCR2 Fc Chimera Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human PDGF-DD (Catalog # 1159-SB/CF) is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human NKp44/NCR2 Fc Chimera Avi-tag (Catalog # AVI2249) binds with an ED 50 of 0.200-1.60 µg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived human NKp44/NCR2 protein

  Human NKp44 (Gln22-Pro190) Accession # CAB52289.1

  IEGRMD

  Human IgG 1 (Pro100-Lys330)

  Avi-tag

  N-terminus

  C-terminus

• Accession #: CAB39168.1
• N-terminal Sequence: Gln22; deduced from Ser23 after deblocking
• Structure / Form: Disulfide-linked homodimer
  Biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 47 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 60-70 kDa, under reducing conditions.

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 3 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human NKp44/NCR2 Fc Chimera Avi-tag Protein, CF

• CD336 antigen
• CD336
• LY95
• LY95lymphocyte antigen 95 homolog (activating NK-receptor; NK-p44)
• lymphocyte antigen 95 (activating NK-receptor; NK-p44)
• Lymphocyte antigen 95 homolog
• natural cytotoxicity triggering receptor 2
• Natural killer cell p44-related protein
• NCR2
• NK cell activating receptor (NKp44)
• NK cell-activating receptor
• NKp44
• NK-p44dJ149M18.1

Background

NKp44, along with NKp30 and NKp46, constitute a group of receptors termed "Natural Cytotoxicity Receptors" (NCR) (1). These receptors are expressed almost exclusively by NK cells and play a major role in triggering NK-mediated killing of most tumor cell lines. No rodent ortholog to NKp44 has been identified. Human NKp44, also known as NCR2, is a 44 kDa type I transmembrane glycoprotein that is characterized by the presence of one extracellular V-like immunoglobulin domain (2). It is synthesized as a 276 amino acid (aa) precursor that contains a 21 aa signal sequence, a 171 aa extracellular region, a 21 aa transmembrane segment and a 63 aa cytoplasmic tail. Alternate splicing in both the cytoplasmic tail and extracellular region generates multiple isoforms of unknown significance. The Ig-like region is unaffected. A physical association with the ITAM-bearing accessory protein, DAP12, occurs via a charged residue in the NKp44 transmembrane domain. Ligation of NKp44 with a specific antibody results in phosphorylation of DAP12 (3) and activation of target cell lysis in a redirected killing assay (4). NKp44 is absent from resting NK cells but is upregulated upon activation with IL-2. Activation-induced expression occurs in the CD56 dim CD16 + NK subset that accounts for more than 85% of NK cells found in peripheral blood and spleen, as well as the CD56 bright CD16 - NK subset that constitutes the majority of NK cells in lymph node and tonsil (5). Studies with neutralizing antibodies reveal that NKp44 is partially responsible for triggering lytic activity against several tumor cell types (2, 6). Blocking any of the individual NCRs results in partial inhibition of tumor cell lysis, but nearly complete inhibition of lysis is observed if all three receptors are blocked simultaneously (6). NKp44 has also been implicated in recognition of virus-infected cells through its capacity to bind to viral hemagglutinins (7). Our Avi-tag Biotinylated human NKp44/NCR2 Fc chimera features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

1. Moretta, L. and A. Moretta (2004) EMBO J. 23:255.
2. Cantoni, C. et al. (1999) J. Exp. Med. 189:787.
3. Augugliaro, R. et al. (2003) Eur. J. Immunol. 33:1235.
4. Vitale, M. et al. (1998) J. Exp. Med. 187:2065.
5. Ferlazzo, G. et al. (2004) J. Immunol. 172:1455.
6. Pende, D. et al. (1999) J. Exp. Med. 190:1505.
7. Arnon, T. et al. (2001) Eur. J. Immunol. 31:2680.

Bioinformatics

• Uniprot:
  • CAB39168.1()